Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Issue 12 (December 2020)

• Record Type: Journal Article
• Authors: Alvarenga, Livia; Salarolli, Roberta; Cardozo, Ludmila F.M.F.; Santos, Rhayssa S.; de Brito, Jessyca S.; Kemp, Julie Ann; Reis, Drielly; de Paiva, Bruna Regis; Stenvinkel, Peter; Lindholm, Bengt; Fouque, Denis; Mafra, Denise
• Is Part Of: Clinical nutrition. Volume 39:Issue 12(2020)
• Page Start: 3594
• Page End: 3600
• Publication Date: 2020-12
• Subjects: Chronic kidney disease -- Curcumin -- Inflammation -- Oxidative stress -- Turmeric; Critically ill -- Nutrition -- Periodicals; Diet therapy -- Periodicals; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; Enteral Nutrition -- Periodicals; Parenteral Nutrition -- Periodicals; Metabolism -- Periodicals; Diétothérapie -- Périodiques; Alimentation parentérale -- Périodiques; Alimentation entérale -- Périodiques; Nutrition -- Périodiques; Diet therapy; Enteral feeding; Nutrition; Parenteral feeding; Electronic journals; Periodicals; Electronic journals; 615.854
• DOI: 10.1016/j.clnu.2020.03.007
• Languages: English
• ISSNs: 0261-5614

Abstract

Summary: Background & aims: Chronic kidney disease (CKD) patients have numerous complications associated with inflammation, which is a potential driver for cardiovascular disease. Curcumin, a compound of the curcuminoid class produced by the Curcuma longa, has been reported to activate nuclear factor erythroid factor 2-related (Nrf2) and inhibit nuclear factor kappa-B (NF-kB). Our aim was to evaluate the effects of curcumin juice on the expression of inflammatory transcription factors in hemodialysis (HD) patients. Methods and results: This double-blind randomized pilot study included 31 HD patients divided into two groups: curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months) and control group (receiving the same juice without curcumin); 14 patients in each arm completed the study. The mRNA expression of Nrf2, NF-kB, NLRP3 inflammasome and IL-1β in peripheral blood mononuclear cells (PBMC; using real-time quantitative polymerase chain reaction, qPCR) and routine biochemistries, food intake and anthropometrics were analyzed. After three months of supplementation, the curcumin group showed a significant decrease in NF-kB mRNA expression (AU) [from 1.08 (0.77–1.38) to 0.52 (0.32–0.95), p = 0.02] and in plasma high sensitivity C-reactive protein (hsCRP) levels [from 3.8 (2.5–6.8) to 2.0 (1.1–3.8) mg/L, p = 0.04]. There was no change in the other evaluated markers. Conclusion: Three months treatment with curcumin in CKD patients undergoing HD resulted in decreased markers of inflammation, NF-kB mRNA expression and hsCRP, suggesting that oral supplementation of curcumin may have an anti-inflammatory effect in this patient group. Trial registration: Approved by the Ethics Committee of the Faculty of Medicine/UFF, number: 2.346.933. This study was registered within ClinicalTrials.gov under the number NCT 03475017. Graphical abstract: Image 1 Highlights: Chronic Kidney Disease patients high inflammation and oxidative stress process. Curcumin is a potential antioxidant and anti-inflammatory natural. mRNA NF-kB expression and hsCRP plasma levels have decreased after curcumin supplementation in hemodialysis patients.